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NBACKGROUND & AIMS: Simultaneous agonism of the
m-opioid receptor and antagonism of the d-opioid receptor
can reduce abdominal pain and diarrhea in patients with
irritable bowel syndrome with diarrhea (IBS-D) without
constipating side effects. We evaluated the efﬁcacy and
safety of a minimally absorbed, m-opioid receptor agonist
and d-opioid receptor antagonist (eluxadoline) in a phase
2 study in patients with IBS-D. METHODS: We
randomly assigned 807 patients to groups that received
oral placebo twice daily or 5, 25, 100, or 200 mg oral
eluxadoline for 12 weeks. The primary end point was
clinical response at week 4, deﬁned by a mean reduction in
daily pain score from baseline of 30%, and of at least 2
points on 010 scale, as well as a stool consistency score
of 3 or 4 on the Bristol Stool Scale (1–7) for at least 66% of
daily diary entries during that week. RESULTS: Signiﬁ-
cantly more patients receiving 25 mg (12.0%) or 200 mg
(13.8%) eluxadoline met the primary end point of clinical
response than patients given placebo (5.7%; P < .05). Pa-
tients receiving eluxadoline at 100 mg and 200 mg also
had greater improvements in bowel movement frequency
and urgency, global symptoms, quality of life, and
adequate relief assessments (P < .05). Additionally, pa-
tients receiving 100 mg (28.0%) or 200 mg (28.5%) elux-
adoline were signiﬁcantly more likely than those receiving
placebo (13.8%; P < .005) to meet the US Food and Drug
Administration response end point during the full 12
weeks of the study. Eluxadoline was well tolerated with a
low incidence of constipation. CONCLUSIONS: In a
phase 2 study of the mixed m-opioid receptor agonist/d-
opioid receptor antagonist eluxadoline vs placebo in
patients with IBS-D, patients given eluxadoline were
signiﬁcantly more likely to be clinical responders,
based on a composite of improvement in abdominal
pain and stool consistency. Further study of eluxado-
line is warranted to assess its potential as a treatment
for IBS-D. ClinicalTrials.gov number, NCT01130272
Keywords: Clinical Trial; Functional Bowel Disorders;
Transit; Drug.
rritable bowel syndrome (IBS) is a common functionalresponse system; MOR, m opioid receptor; WAP, worst abdominal pain.
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Open access under CC BY-NC-ND license.Igastrointestinal disorder that affects approximately
10%15% of the population in Western countries.1 IBS
is characterized by recurrent abdominal discomfort and
pain associated with altered bowel habits.2 Currently, IBSsubtypes are determined by stool consistency pattern and
include diarrhea (IBS-D), constipation , or mixed con-
stipation and diarrhea. IBS can negatively impact an in-
dividual’s quality of life and results in signiﬁcant direct
and indirect costs.3 Current safe and effective pharmaco-
logic treatments for IBS-D are limited and include anti-
spasmodics, antidepressants, antidiarrheal agents, and
alosetron.4
Opioid receptors, including m, d, and k, are expressed
along the gastrointestinal tract and play a key role in
regulating gastrointestinal motility, secretion, and visceral
sensation.5,6 Exogenous opioids reduce gastrointestinal
transit through activation of m-opioid receptor (MOR)
and can treat diarrhea in acute situations.7 Agents that
simultaneously activate MOR and antagonize d-opioid
receptor (DOR) have differential gastrointestinal effects
and can possess increased analgesic potency compared
with pure MOR agonists.8,9 Such a mixed MOR agonist/
DOR antagonist proﬁle can offer an advantage in treating
both the diarrhea and abdominal pain associated with
IBS-D.
Eluxadoline (nonproprietary name adopted by US
Adopted Names Council; International Non-proprietary
Name Committee pending) is a locally active, mixed
MOR agonist/DOR antagonist with low oral bioavail-
ability that is being developed for the treatment of IBS-D.
In vitro, eluxadoline reduces contractility in intestinal
tissue and inhibits neurogenically mediated secretion.10
In vivo, eluxadoline reduces gastrointestinal transit and
fecal output in stressed and nonstressed mice over a wide
dose range without fully inhibiting gastrointestinal
transit.11 In contrast, loperamide had a narrow dose range
in the same stressed and nonstressed models and
completely prevented fecal output in a dose-dependent
manner.11 These data support the hypothesis that mixed
MOR agonism/DOR antagonism can treat IBS-D without
constipating side effects.
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doses of eluxadoline were previously evaluated in a phase 1
study in healthy adults. This phase 2, proof-of-concept
study evaluated the efﬁcacy, safety, and tolerability of
orally administered eluxadoline in patients with IBS-D.Materials and Methods
Study Design
This phase 2 randomized, double-blind, placebo-
controlled study enrolled patients from May 2010 until April
2011 at 263 primary and tertiary care centers within the United
States. The trial was designed, conducted, and reported in
compliance with the principles of Good Clinical Practice guide-
lines. An Institutional Review Boardapproved informed con-
sent was reviewed and signed by all patients before their
participation in this trial.
This study consisted of an initial prescreening period, a
screening period of 2 to 3 weeks, a 12-week double-blind treat-
ment period, and a 2-week post-treatment period. During the
1-week prescreening period, patients underwent a physical ex-
amination, provided blood and urine for routine testing, and
discontinued any prohibited medications. Patients who met the
inclusion and exclusion criteria entered the screening period and
began using an interactive voice response system (IVRS) to pro-
vide daily symptom assessments. After the screening period of
23 weeks, patients who continued to meet eligibility criteria
and were compliant with the IVRS system for at least 6 of 7 days
during the week before and 11 of 14 days during the 2 weeks
before were randomized in parallel, 1:1:1:1:1 to receive placebo or
eluxadoline 5, 25, 100, or 200 mg twice daily with breakfast and
dinner. Randomization schedules were generated by an un-
blinded clinical research organization using the Plan procedure
in SAS (version 9.1) with a minimum block size. The IVRS
implemented the randomization, balancing sex across assigned
treatment groups, and assigned the appropriate materials kit to
the patient; site personnel dispensed the assigned materials. Pa-
tients returned for follow-up visits at weeks 2, 4, 8, and 12 and
had a post-treatment assessment at week 14. All personnel
involved in the design and implementation of the trial remained
blinded until the database was locked, with the exceptions of the
statisticians who generated the randomization schedule and the
IVRS developers.
Daily IVRS measurements included worst abdominal pain
(WAP), stool consistency, bowel frequency, rectal urgency, and
frequency of stool incontinence. Weekly measurement included
the IBS Global Symptom score on a 04 scale (0 ¼ none, 1 ¼
mild, 2 ¼ moderate, 3 ¼ severe, 4 ¼ very severe), where patients
were asked “How would you rate your IBS symptoms overall over
the past 7 days?” During monthly clinic visits, patients
completed patient-reported outcomes questionnaires, including
the IBS-Symptom Severity Score (IBS-SSS; scaled 0500 with
higher scores indicating more severe symptoms), IBS-quality of
life (IBS-QOL; scaled 0100 with higher scores indicating better
quality of life), and EuroQoL-5 Dimension (EQ-5D; scaled 01
with lower scores indicating better quality of life) and answered
the question “Over the past week have you had adequate relief of
your IBS symptoms?” Safety assessments included capture of
adverse events, clinical laboratory results, 12-lead electrocardio-
grams, vital signs, and physical examinations.
As an additional safety precaution, IVRS-generated notiﬁca-
tions were sent to investigators to discontinue patients from thestudy for IVRS-conﬁrmed constipation if the patients’ diary
entries indicated a lack of a bowel movement on 4 consecutive
days on more than one occasion or the lack of a bowel movement
on any 7 consecutive days (irrespective of whether an adverse
event of constipation was reported). Additionally, the absence of
diary entry on a given day was treated as the absence of a bowel
movement by the IVRS; programmatic IVRS study withdrawal
notiﬁcations were generated for patients that were noncompliant
with the IVRS for the same criteria as the absence of a bowel
movement.Study Population and Sample Size
Eligible patients were male or female aged 18 to 65 years
who met the Rome III criteria for IBS-D,3 and who reported a
mean daily WAP score of 3.0 (on a 010 numerical rating scale,
where 0 indicates no pain and 10 worst pain imaginable) and
mean daily stool consistency score of 5.5 on the Bristol Stool
Scale (1 ¼ hard, lumpy stools and 7 ¼ watery, liquid stools) in
the week before randomization. Patients were also required to
have had a colonoscopy within the past 5 years for any alarm
feature, such as weight loss, nocturnal symptoms, familial his-
tory of colon cancer, or blood mixed with stool. Patients with
histories of inﬂammatory bowel disease, celiac disease, intestinal
obstruction, stricture, toxic megacolon, gastrointestinal perfora-
tion, fecal impaction, gastric banding, bariatric surgery, adhe-
sions, ischemic colitis, impaired intestinal circulation, major vein
thrombophlebitis, hypercoagulable states, major gastric, hepatic,
pancreatic, or intestinal surgery, or evidence of signiﬁcant he-
patic or renal disease were excluded. Patients agreed to remain on
a stable diet. Female patients of child-bearing potential agreed to
use adequate birth control throughout the trial. Stable doses of
medications for depression, migraine, anxiety, or other chronic
conditions were permitted. However, antibiotics, anticholiner-
gics, cholestyramine, cholinomimetics, opioids, colchicine, doc-
usate, enemas, gastrointestinal preparations, 5-HT3 antagonists,
and 5-HT4 agonists were required to be discontinued for at least
21 days before randomization. Nonsteroidal anti-inﬂammatory
drugs used speciﬁcally for IBS symptoms were prohibited from
14 days before randomization.Rescue Medication
Rescue medication was allowed after randomization to
mitigate the potential for attrition or unwillingness to enter the
study. Single-blind placebo rescue (weeks 14) followed by
single-blind loperamide (2 mg/unit dosage, weeks 512) was
allowed for uncontrolled diarrhea and acetaminophen was
allowed for uncontrolled abdominal pain (weeks 112). Patients
were withdrawn if they exceeded the maximum allowable dosages
of antidiarrheal rescue, which were 4 unit doses in any 24-hour
period, 7 unit doses in any 48-hour period, or 11 unit doses in
any 7-day period.Study Outcomes
The primary end point was the percentage of patients who
achieved clinical response at week 4, deﬁned as a patient who re-
ported a decrease in the mean daily WAP scores from baseline by
30% and at least 2 points and a daily Bristol Stool Scale score of
3 or 4 on 66% of daily diary entries within that week.
Secondary end points included the percentage of patients who
achieved clinical response at week 12 and the percentage of pa-
tients who achieved response to the individual WAP and stool
consistency components at weeks 4 and 12. Other secondary and
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frequency, urgency, and incontinence, IBS Global Symptom
score, IBS-SSS, IBS-adequate relief, and quality of life assess-
ments based on the IBS-QOL and EQ-5D questionnaires.
After initiation of the study, the US Food and Drug Admin-
istration (FDA) issued recommendations for outcomes measures
in IBS clinical trials. Consequently, after discussions with the
FDA, post-hoc analyses were conducted based on the FDA rec-
ommended daily responder deﬁnition,11 where patients were
FDA responders if on at least 50% of days during the 12 weeks of
the study their daily WAP score was reduced from baseline by
30% and they had either a daily Bristol Stool Scale score <5 or
reported no bowel movement. FDA response was also assessed
over each individual month of the study (ie, weeks 14, 58, and
912). Additionally, responses to the individual WAP and stool
consistency components of the FDA response deﬁnition were
assessed during the entire 12 weeks of the study and over each
monthly interval as post-hoc analyses.Statistical Analyses
The study was prospectively powered based on clinical
response at week 4, assuming a response rate of 30% for at least
one eluxadoline group and 15% for placebo. Assuming a
1-month dropout rate of 13%, 170 patients per group yields
approximately 85% power comparing any single eluxadoline
group to placebo using Fisher exact test with a 2-sided a-level of
.05. Logistic models with covariates were assumed to have at least
as much power as the Fisher exact test and so, for the a priori
analyses, the 85% power was seen as a lower bound. An interim
analysis was prospectively planned and executed by an inde-
pendent interim analysis committee when approximately 85
patients per group had completed at least 4 weeks of treatment.
No a priori stopping rules were developed, however, a prospective
charter allowed the interim analysis committee to discontinue
one or more arms based on safety, tolerability, lack of efﬁcacy, or
business considerations. Randomization would continue until
approximately 170 patients were enrolled in each of the
remaining groups.
The primary end point of clinical response was analyzed ac-
cording to the ﬁnal statistical analysis plan prospectively
implemented before database lock and unblinding. Clinical
response at weeks 4 and 12 was analyzed via a logistic regression
using a generalized linear mixed effects model (GLMM) with
center as a random effect and baseline WAP and stool consis-
tency scores as covariates. Patients with <5 diary entries within
week 4 or week 12 were categorized as nonresponders for that
week. No imputation of data was performed if a diary entry was
missed. Odds ratios from the logistic regressions were used to
determine statistical signiﬁcance of treatment effects as
compared with placebo. The end points of bowel movement
frequency, urgency episodes, and incontinence were modeled
using a GLMM with ﬁxed effects of treatment, time, and the
treatment by time interaction; respective baseline frequencies
were ﬁtted in the model as baseline covariates. Additionally, a
random effect was ﬁt with patients as sampling units to account
for repeated measurements of each outcome. Because outcomes
were counts of events and likely non-normally distributed, the
GLMMs were ﬁt assuming a Poisson response distribution and a
natural log link function.12,13
Other secondary and exploratory end points were modeled
with similar GLMMs. IBS Global Symptom score was modeled as
a normal response distribution (identity link) with ﬁxed and
random effects similar to count data, with the exception that thebaseline covariate was not included because of not having
collected a baseline assessment. IBS-SSS, IBS-QOL, and EQ-5D
scores were modeled with ﬁxed effects of treatment, time, and
the treatment by time interaction, the baseline score, and a
random effect to account for repeated measurements. The
models for IBS-QOL and EQ-5D assumed a normal distribution
and identity link. IBS-adequate relief was modeled like the IBS
Global Symptom score (ie, with no baseline covariate), but
assuming a binary distribution and logit link function.
The time metrics ﬁt for the GLMM models reﬂected the fre-
quency with which a given outcome variable was collected, for
example, daily for bowel movements and weekly for global
symptoms. Differences in GLMM model estimates were evalu-
ated for statistical signiﬁcance at days 28, 56, and 84 to sum-
marize outcomes after 1, 2, and 3 months of treatment,
respectively. Note that interpretation of treatment group effects
for GLMMs depends on the link function used. Therefore, all
models of binary outcomes result in effects that are odds ratios,
count variable models result in risk ratios, and normally
distributed variable models using the identity link function have
the usual interpretation of effects being mean differences.
Post-hoc FDA response based on daily responder criteria—where
patients must have met both WAP and stool consistency
response criteria on a given day—was evaluated during the full
12-week interval and each monthly interval using a logistic
regression model, controlling for baseline values of WAP, stool
consistency scores, and bowel movement frequency. Minimal
compliance criteria of 70% were required within the intervals
analyzed; patients with <60 diary entries during the 12-week
interval were categorized as nonresponders for the study and
patients with <20 diary entries during any 4-week interval were
categorized as nonresponders for that month. No imputation of
data was performed if a diary entry was missed.
All authors had access to the study data and reviewed and
approved the ﬁnal manuscript.Results
Participant Flow
Of the 807 patients randomized, 525 patients
completed the trial and 282 discontinued treatment
(Supplementary Figure 1). Reasons for discontinuation
included 54 patients who were noncompliant with the
daily IVRS, 43 patients who voluntarily withdrew, 42 pa-
tients who experienced adverse events, and 38 patients in
the 5-mg eluxadoline group who discontinued when the
treatment arm was deselected because of lack of efﬁcacy.
Discontinuations due to adverse events were more com-
mon among patients receiving 200 mg eluxadoline.
Eighteen patients were enrolled at a site terminated by
Furiex for potential scientiﬁc misconduct identiﬁed dur-
ing routine site auditing and were excluded from analysis.
Of the remaining 789 patients randomized, 771 patients
received at least 1 dose of study drug (safety set) and 754
received at least 1 dose of study drug and had at least
1 post-randomization assessment of the primary outcome
(intent-to-treat set). Baseline characteristics in the intent-
to-treat set were similar across groups, although patients
in the 100-mg eluxadoline group had a slightly higher
mean baseline pain score (Table 1). Patients averaged 4
to 5 bowel movements per day. More than 60% of patients
Table 1. Demographics and Baseline Characteristics (Intent-To-Treat Population)
Characteristic
Eluxadoline
Placebo (n ¼ 159)5 mg (n ¼ 105) 25 mg (n ¼ 167) 100 mg (n ¼ 163) 200 mg (n ¼ 160)
Age, mean (SD) 45.5 (12.9) 45.6 (11.9) 43.6 (10.9) 44.8 (11.7) 44.6 (12.5)
Male, n (%) 31 (30) 51 (31) 50 (31) 47 (29) 49 (31)
Female, n (%) 74 (70) 116 (69) 113 (69) 113 (71) 110 (69)
Pain, mean (SD) 5.8 (1.54) 5.9 (1.70) 6.1 (1.72) 5.8 (1.48) 5.9 (1.67)
Stool consistency, mean (SD) 6.2 (0.45) 6.2 (0.40) 6.2 (0.43) 6.2 (0.42) 6.2 (0.44)
BM frequency, mean (SD) 4.6 (2.47) 4.4 (3.16) 5.1 (3.59) 5.0 (3.21) 4.9 (3.57)
Urgency, mean (SD) 3.1 (1.96) 3.0 (2.92) 3.5 (3.32) 3.3 (2.33) 3.3 (3.15)
Incontinence, mean (SD) 1.1 (1.64) 0.9 (1.95) 1.1 (2.20) 0.9 (1.35) 1.1 (2.63)
NOTE. Baseline values represent daily averages for the 7 days before randomization for worst abdominal pain scores (on 010 numeric rating scale),
stool consistency scores (on 17 Bristol Stool Scale), and daily averages for the number of daily bowel movements, and episodes of urgency and
incontinence.
BM, bowel movement.
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symptoms (ie, scores >300).14Table 2
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Primary and secondary end points. Evaluating the
prespeciﬁed primary end point at week 4 (Table 2),. Primary and Secondary Efﬁcacy Results: Clinical Respons
Elu
5 mg (n ¼ 105) 25 mg (n ¼ 167)
end point
l response
k 4
omposite, % 12.4a 12.0b
R (95% CI) 2.46 (0.996.08) 2.38 (1.045.48)
bdominal pain, % 39.0 40.7
R (95% CI) 1.06 (0.621.81) 1.08 (0.671.72)
tool consistency, % 12.4 16.8b
R (95% CI) 1.58 (0.703.58) 2.38 (1.184.80)
ry end points
l response
k 12
omposite, % 8.6 13.2
R (95% CI) 0.72 (0.311.69) 1.21 (0.622.37)
bdominal pain, % 30.5 39.5
R (95% CI) 0.66 (0.391.14) 0.99 (0.631.56)
tool consistency, % 10.5 19.2
R (95% CI) 0.65 (0.301.41) 1.36 (0.752.47)
ate relief response
k 4, n 103 163
es, % 59.1 62.4a
R (95% CI) 1.49 (0.802.76) 1.71 (0.992.95)
k 8
es, % 63.2 64.2b
R (95% CI) 1.51 (0.902.55) 1.58 (1.012.47)
k 12
es, % 67.0 65.9
R (95% CI) 1.54 (0.693.44) 1.47 (0.762.83)
rall study
50.5 55.2
R (95% CI) 1.18 (0.711.94) 1.42 (0.912.22)
esponse rates and odds ratios (OR) (95% conﬁdence interval [CI]) a
nts included. Patients were considered responders if they met the c
sistency (or its individual pain and stool consistency parts), or if
e relief of your IBS symptoms?” (Adequate Relief Response). Patients
d “Yes” for at least 2 of the 3 weeks. The numbers per group repr
compared with placebo.
compared with placebo.signiﬁcantly more patients in the intent-to-treat popula-
tion receiving 25 mg (12.0%; P ¼ .041) and 200 mg elux-
adoline (13.8%; P ¼ .015) were clinical responders
compared with placebo patients (5.7%). Although the
100-mg eluxadoline group did not achieve statistical sig-
niﬁcance at week 4, a similar trend for improvement overe Criteria (Intent-to-Treat Population)
xadoline
Placebo (n ¼ 159)100 mg (n ¼ 163) 200 mg (n ¼ 160)
11.0a 13.8b 5.7
2.08 (0.894.84) 2.80 (1.236.38)
39.3 39.4 39.6
0.99 (0.621.60) 1.02 (0.641.64)
14.1a 18.1b 8.2
1.90 (0.923.92) 2.61 (1.295.26)
20.2b 15.0 11.3
2.01 (1.073.80) 1.40 (0.722.72)
49.1a 36.3 39.6
1.49 (0.942.34) 0.86 (0.541.37)
22.1a 20.0 15.1
1.64 (0.912.94) 1.44 (0.792.61)
156 150 153
69.3b 67.4b 49.3
2.32 (1.324.07) 2.12 (1.203.74)
74.9b 71.5b 53.1
2.63 (1.664.18) 2.22 (1.383.57)
79.7b 75.4b 56.8
2.99 (1.496.00) 2.33 (1.134.82)
63.5b 59.3b 46.4
2.01 (1.273.16) 1.69 (1.072.66)
re based on model estimates from the logistic regression with covariate
linical response deﬁnition for the composite of worst abdominal pain and
they answered “Yes” to the question “Over the past week have you had
were considered an adequate relief responder for the overall study if they
esent those for whom adequate relief was collected.
Figure 1. Bowel function as-
sessments over time. Patient-
reported averages plotted over
time are presented for each
active eluxadoline group vs
placebo for (A) daily bowel
movement frequency; (B) daily
urgency episodes; and (C) daily
incontinence episodes.
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a signiﬁcantly greater percentage of patients receiving
100 mg eluxadoline (20.2%; P ¼ .030) were clinical re-
sponders compared with placebo patients (11.3%). The 25-
mg and 200-mg eluxadoline groups were not signiﬁcantly
different than placebo at week 12. Pain response rates at
week 4 based on the WAP component of the clinical
response deﬁnition were not different from placebo for
any eluxadoline group (Table 2). A trend toward higher
pain response rates was observed for the 100-mg elux-
adoline group (49.1%; P ¼ .087) compared with placebo
(39.6%) at week 12. Stool consistency response rates at
week 4 were signiﬁcantly higher for the 25-mg (16.8%; P ¼
.016) and 200-mg (18.1%; P ¼ .008) eluxadoline groups
compared with placebo (8.2%) with a similar trend
observed for the 100-mg eluxadoline group (14.1%; P ¼
.083). At week 12, a similar trend toward higher stool
consistency response rates was seen for the 100-mg elux-
adoline group (22.1%; P ¼ .098) compared with placebo
(15.1%). Rescue medication use for uncontrolled abdom-
inal pain and diarrhea was uncommon and similar across
all groups. Importantly, no difference in antidiarrheal
rescue medication use was observed between the ﬁrst
month of the study and the last 2 months of the study.
During both time periods, patients averaged <1 unit doseper week. Use of rescue medication for abdominal pain
was even more rarely reported. Overall, use of rescue
medication did not impact analyses of WAP, stool con-
sistency, or composite response based on multiple sensi-
tivity analyses (data not shown).
Patients treated with eluxadoline also reported experi-
encing adequate relief of their IBS symptoms to a greater
extent than placebo patients (Table 2). Patients receiving
100 mg (odds ratios ¼ 2.32, 2.63, and 2.99; P ¼ .004,
P < .001, and P ¼ .002, respectively) and 200 mg (odds
ratios ¼ 2.12, 2.22, and 2.33; P ¼ .009, P ¼ .001, and P ¼
.023, respectively) eluxadoline were more likely than pla-
cebo patients to report adequate relief of their IBS
symptoms at weeks 4, 8, and 12. Likewise, a signiﬁcantly
greater percentage of patients receiving 100 mg (63.5%,
odds ratio ¼ 2.01; P ¼ .003) and 200 mg (59.3%, odds
ratio ¼ 1.69; P ¼ .025) eluxadoline reported adequate re-
lief of their IBS symptoms on at least 2 of the 3 monthly
assessments compared with placebo patients (46.4%).
Decreasing counts for daily bowel movements, urgency
episodes, and incontinence episodes were observed for all
groups during the 3 months of treatment. The onset of the
effect was rapid from the start of dosing for all bowel mea-
surements, with differences from placebo generally reaching
peak effects between the second and thirdmonths (Figure 1).
Figure 2. Global Symptom as-
sessments and quality of life
measures over time. Patient-
reported averages plotted over
time are presented for each
active eluxadoline group vs pla-
cebo for: (A) weekly IBS Global
Symptom score; (B) monthly
IBS-SSS; and (C) monthly
IBS-QOL. Error bars represent
1 SEM.
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movements for patients receiving 100 and 200 mg eluxado-
line were 0.88 (P¼ .006) and 0.78 (P< .001), 0.88 (P¼ .011)
and 0.80 (P< .001), and 0.89 (P¼ .022) and 0.82 (P< .001) at
days 28, 56, and 84, respectively. Likewise, relative risk esti-
mates for urgency episodes for patients receiving100 and200
mg eluxadoline were 0.74 (P¼ .008) and 0.65 (P< .001), 0.76
(P ¼ .013) and 0.67 (P < .001), and 0.77 (P ¼ .024) and 0.69
(P¼ .002) at days 28, 56, and 84, respectively. No signiﬁcant
differences from placebo in incontinence episodes were
observed. However, a trend for improvements in
incontinence-free days was noted for patients who averaged
at least 1 incontinent episode per day in the week before
randomization (38.8 vs 26.5 incontinence-free days for 100-
mg eluxadoline patients compared with placebo patients,
respectively; P ¼ .078). Although changes over time in
abdominal pain and stool consistency were only analyzed via
the response deﬁnitions speciﬁed in the primary and sec-
ondary end points, reductions from baseline values followed
a similar time course to those shown for the other bowel
characteristics (data not shown). During the 2-week follow-
up period after week 12, values for abdominal pain, stool
consistency, and bowel characteristics began to increase for
all treatment groups, but remained below baseline levels.Consistent improvement during the course of the study
was also seen in patients’ ratings of their global IBS
symptoms, with peak effects again observed between the
second and third months (Figure 3). For IBS Global
Symptom scores, mean differences from placebo were
statistically signiﬁcant for patients receiving 200 mg
eluxadoline (0.26; P < .001) at week 4 and for both
the 100-mg (0.19 and 0.26; P ¼ .014 and 0.003,
respectively) and 200-mg (0.30 and 0.34; P < .001 and
< .001, respectively) eluxadoline groups at weeks 8 and 12.
Likewise for IBS-SSS, mean differences from placebo were
statistically signiﬁcant for the 100-mg eluxadoline group
at the end of weeks 4, 8, and 12 (16.69, 33.55,
and 50.40; P ¼ .011; P < .001; and P < .001, respectively)
and for the 200-mg eluxadoline group at the end of weeks
8 and 12 (19.89 and 27.48; P ¼ .012 and P ¼ .011,
respectively). Patients who received eluxadoline also re-
ported signiﬁcant improvement in their quality of life
(Figure 2). A greater improvement in IBS-QOL total scores
was observed for patients receiving 100 mg and 200 mg
eluxadoline compared with placebo at the end of weeks 4,
8, and 12. For patients receiving 100 mg eluxadoline,
mean differences from placebo were 3.05 (P ¼ .012), 5.82
(P < .001), and 8.60 (P < .001). For patients receiving 200
Table 3. Post-Hoc Efﬁcacy Results: FDA Response Criteria (Intent-to-Treat Population)
Eluxadoline
Placebo (n ¼ 159)5 mg (n ¼ 105) 25 mg (n ¼ 167) 100 mg (n ¼ 163) 200 mg (n ¼ 160)
FDA response (full study)
Weeks 112
Composite, % 13.3 16.9 28.0a 28.5a 13.8
90% CI 0.96 (0.471.95) 1.28 (0.702.32) 2.43 (1.384.28) 2.50 (1.424.40)
Abdominal pain, % 34.8 46.7 55.2a 46.6 43.9
90% CI 0.68 (0.411.14) 1.12 (0.721.74) 1.57 (1.012.45) 1.11 (0.721.73)
Stool consistency, % 20.1 21.4 33.4b 36.9a 23.8
90% CI 0.80 (0.441.46) 0.87 (0.521.46) 1.60 (0.982.62) 1.86 (1.143.04)
FDA response (by month)
Weeks 14, n 105 167 163 160 159
Composite, % 10.8 14.3 21.1 23.7b 15.8
90% CI 0.65 (0.311.35) 0.89 (0.491.63) 1.43 (0.812.52) 1.66 (0.952.91)
Abdominal pain, % 39.4 44.9 44.8 42.7 41.9
90% CI 0.90 (0.541.49) 1.13 (0.731.76) 1.13 (0.721.76) 1.03 (0.661.61)
Stool consistency, % 20.5 22.3 30.6a 38.6a 20.2
90% CI 1.02 (0.551.87) 1.13 (0.671.93) 1.74 (1.042.90) 2.48 (1.504.11)
Weeks 58, n 90 146 137 125 139
Composite, % 26.9 23.3 37.8a 40.2a 21.8
90% CI 1.32 (0.712.45) 1.09 (0.621.91) 2.18 (1.283.72) 2.41 (1.404.15)
Abdominal pain, % 53.1 58.4 64.5 59.1 59.7
90% CI 0.76 (0.451.31) 0.95 (0.591.52) 1.22 (0.751.99) 0.97 (0.591.60)
Stool consistency, % 30.4 28.8 45.9a 47.4a 30.3
90% CI 1.00 (0.561.79) 0.93 (0.561.56) 1.95 (1.193.21) 2.07 (1.253.44)
Weeks 912, n 72 137 129 109 126
Composite, % 22.6 30.3 44.3a 46.3a 25.5
90% CI 0.85 (0.431.68) 1.27 (0.742.20) 2.33 (1.373.98) 2.52 (1.454.40)
Abdominal pain, % 45.4 56.5 71.0a 68.8b 56.2
90% CI 0.65 (0.361.16) 1.01 (0.621.65) 1.90 (1.133.20) 1.71 (1.002.94)
Stool consistency, % 25.5 35.1 48.2a 56.6a 32.5
90% CI 0.71 (0.371.36) 1.13 (0.671.89) 1.93 (1.163.23) 2.71 (1.584.64)
NOTE. Response rates and odds ratios (OR) (90% conﬁdence intervals [CI]) are based on model estimates from the logistic regression with covariate
adjustments included. Patients were considered responders if they met the FDA daily responder deﬁnition for the composite of worst abdominal pain
and stool consistency (or its individual pain and stool consistency parts) for at least 50% of time over the interval from weeks 112 or over each
monthly interval. Patients were included in a monthly interval if they received at least one dose of study medication within that interval.
aP < .05 compared with placebo.
bP < .10 compared with placebo.
August 2013 ELUXADOLINE FOR TREATMENT OF IBS-D 335
C
LI
N
IC
A
L
A
Tmg eluxadoline, mean differences were 3.31 (P ¼ .007),
5.75 (P < .001), and 8.19 (P < .001) at the end of weeks 4,
8, and 12. Results from the EQ-5D questionnaire also
revealed a statistically signiﬁcant difference (P < .001)
from placebo for patients in the 100-mg eluxadoline
group at both weeks 8 and 12; however, mean EQ-5D
results for all groups remained within normal ranges for
the population throughout the course of the study.
FDA end points. In the post-hoc analysis of the
FDA end point, FDA response rates during the full
12-week interval were statistically superior for patients
receiving 100 mg (28.0%; P ¼ .002) and 200 mg (28.5%;
P ¼ .002) eluxadoline compared with placebo (13.8%)
(Table 3); patients receiving eluxadoline at 100 mg and
200 mg were more than twice as likely as placebo patients
to be responders. A signiﬁcantly higher pain response
based on the WAP component of the FDA response deﬁ-
nition was also seen for the 100-mg eluxadoline group
(55.2%; P ¼ .045) compared with placebo (43.9%). Stool
consistency response based on the stool consistency
component of the FDA response deﬁnition was signiﬁ-
cantly higher for patients receiving 200 mg eluxadoline
(36.9%; P ¼ .013) compared with placebo (23.8%), with asimilar trend observed for 100-mg eluxadoline patients
(33.4%; P ¼ 0.059). Post-hoc monthly analyses during the
intervals from weeks 14, 58, and 912 showed a
consistently durable effect for overall FDA response, with
rates for patients receiving 100 mg and 200 mg eluxado-
line being statistically superior to placebo over the latter
2 intervals (Table 3).Safety and Tolerability
Adverse event rates were similar across all groups
and showed no obvious dose-dependent trend from 5 mg
to 100 mg; however, patients in the 200-mg eluxadoline
group reported higher rates of severe events, adverse
events leading to discontinuation, and nonserious
gastrointestinal and central nervous system events
(Table 4). The most common gastrointestinal events re-
ported were nausea, abdominal pain, vomiting, and con-
stipation—the majority showing the highest rates in the
200-mg eluxadoline group. Although the rate of con-
stipation was highest for the 100-mg eluxadoline group,
none of the adverse events of constipation reported by
these patients led to discontinuation or was rated severe in
intensity. A total of 5 adverse events of patient-reported
Table 4. Most Commonly Reported Treatment-Emergent Adverse Events (Safety Population)
Eluxadoline
Placebo (n ¼ 159)5 mg (n ¼ 105) 25 mg (n ¼ 170) 100 mg (n ¼ 165) 200 mg (n ¼ 172)
At least 1 TEAE 46 (44) 86 (51) 73 (44) 90 (52) 78 (49)
Nausea 6 (6) 11 (6) 9 (5) 18 (10) 7 (4)
Headache 3 (3) 12 (7) 5 (3) 7 (4) 6 (4)
Nasopharyngitis 4 (4) 8 (5) 7 (4) 6 (4) 6 (4)
Abdominal pain 3 (3) 6 (4) 4 (2) 13 (8) 3 (2)
Dizziness 4 (4) 4 (2) 5 (3) 11 (6) 4 (3)
Vomiting 1 (1) 7 (4) 7 (4) 12 (7) 1 (1)
Constipation 2 (2) 5 (3) 10 (6) 6 (3) 4 (3)
NOTE. Values are n (%).
TEAC, treatment-emergent adverse event.
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200-mg eluxadoline group and 1 in the placebo group.
Four patients discontinued from the study because of
IVRS-conﬁrmed constipation; 2 of these 4 patients also
reported adverse events of constipation (which did not
contribute to discontinuation) coincident to the IVRS
data (one each in the 25-mg and 100-mg eluxadoline
groups). No serious adverse events of constipation were
reported.
Three serious adverse events of pancreatitis were re-
ported by patients during treatment with eluxadoline (2 at
200 mg and 1 at 25 mg). The 2 pancreatitis events at 200
mg occurred within the ﬁrst 2 doses of study medication
and the event at 25 mg occurred after 18 days of twice
daily dosing; all resolved rapidly without sequelae. Among
these 3 cases, one 200-mg event was confounded by a
documented blood alcohol level of 76 mg/dL at the time
of the event and a recent hospitalization for alcoholic
pancreatitis 2 months before study entry. A fourth case of
pancreatitis, which was also transient in nature, occurred
approximately 15 days after the patient’s last dose of 100
mg eluxadoline; this event occurred when the patient was
being treated for bronchitis with clarithromycin. All
4 cases of pancreatitis were unblinded on the reporting of
this last case and were determined to have occurred in the
eluxadoline treatment arms.
Results from routine laboratory evaluations, vital sign
measurements, physical examinations, and electrocardio-
grams were unremarkable and revealed no treatment-
related effects.Discussion
Eluxadoline is a mixed MOR agonist/DOR antag-
onist under development as a potential treatment for
IBS-D. Although centrally acting mixed MOR agonist/
DOR antagonist compounds have been investigated for
potential analgesic advantages over pure MOR agonists,
eluxadoline is being evaluated speciﬁcally for its peripheral
effects because it has very low bioavailability when
administered orally.11 In animal models of altered
gastrointestinal function, eluxadoline has demonstrated
the ability to normalize fecal output over a wide dose
range without completely blocking gastrointestinal
transit, unlike the pure MOR agonist loperamide.11 Thesedata provide the rationale to evaluate the effectiveness of
eluxadoline to treat the symptoms of IBS-D. In this phase
2 clinical trial, eluxadoline treatment resulted in statisti-
cally signiﬁcantly greater percentages of patients with
IBS-D who met the primary end point of clinical response
at week 4 compared with placebo treatment.
All response rates for the primary end point were
modest, despite odds ratios for eluxadoline groups
exceeding 2 when compared with placebo (results statis-
tically signiﬁcant for 25 mg and 200 mg eluxadoline).
These overall low response rates for the primary end point
might be primarily attributable to the composite nature of
the clinical response deﬁnition, namely the requirement
that a patient meet the prespeciﬁed improvements in both
worst abdominal pain and stool consistency in the same
week. Patients had to ﬁrst be dichotomized as either re-
sponders or nonresponders for each of the individual
components of the composite, and only if they were re-
sponders for both were they categorized as a clinical
responder. The combination of these 2 dichotomous
criteria was therefore quite restrictive and appears to be
overburdened by the more discriminatory of the 2, spe-
ciﬁcally the requirement to meet a stool consistency score
of 3 or 4 on at least 2 of 3 of the daily diary entries in a
week. When evaluating week 4 response rates for the in-
dividual components of the composite response deﬁni-
tion, eluxadoline treatment yielded abdominal pain
responses of approximately 40% across groups (not
signiﬁcantly different from placebo) and stool consistency
responses of <20% (statistically signiﬁcant for 25 mg and
200 mg eluxadoline). The latter response rates (ie, stool
consistency response) are more consistent with those of
the composite response and appear to drive the low overall
response rates for the primary end point.
The rigor of the composite is further illustrated by the
very low placebo response reported for the primary end
point; this stands in contrast to the well-documented high
placebo response in IBS.15 A recent meta-analysis of ran-
domized clinical trials in IBS suggests a mean placebo
response rate of approximately 40% based on various global
response criteria, including binary outcomes such as pa-
tients’ subjective assessments of relief.16 In the present
study, placebo responses rates for the secondary end point
of adequate relief of IBS symptoms were more consistent
with the historical rates, with values of approximately 50%
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effects for eluxadoline were more robust when assessed by
this measure, with patients treated at 100 mg and 200 mg
signiﬁcantly more likely than placebo patients to perceive
that their IBS symptoms were adequately relieved (odds
ratios >2 for all 3 monthly assessments).
The treatment effects of eluxadoline appeared to in-
crease with time on treatment. Although only signiﬁcant
over placebo for the 100-mg eluxadoline group, response
rates based on the protocol-speciﬁed composite were
greater for all treatment groups at week 12 than at the
time of the primary end point at week 4. Effects for the
secondary end points of bowel movement frequency, ur-
gency, global symptom scores, and quality of life followed
a similar time course, with maximal improvements over
placebo generally observed between the second and third
month of treatment. However, a higher degree of vari-
ability in the data collected during the latter part of the
study (as shown in Figures 2 and 3) precludes any deﬁn-
itive conclusion on whether the effects of eluxadoline
might regress after 2 to 3 months of treatment or if the
effect persists with continued treatment. This will need to
be evaluated in future studies of longer duration. Impor-
tantly, data collected during the 2-week follow-up period
in this study revealed no rebound worsening for any of the
secondary end point measures after stopping treatment.
As a supplemental evaluation of efﬁcacy, post-hoc an-
alyses were conducted in accordance with the end-point
recommendation of the FDA guidance on IBS.12
Although the nature of the primary end point speciﬁed
in the protocol was consistent with the recommendations
of the FDA (ie, a composite of improvement in pain and
stool consistency), it differs from the suggested FDA end
point by evaluating clinical response only during the 7
days of week 4 rather than during the entire 12 weeks of
treatment. By contrast, the post-hoc FDA analyses encom-
passed all 12 weeks of efﬁcacy data and required responders
to achieve daily improvements in abdominal pain and stool
consistency for at least 50% of time on study. In those an-
alyses, FDA composite response rates for both the 100-mg
and 200-mg eluxadoline groups were signiﬁcantly greater
than placebo (odds ratios >2) and demonstrated a more
discernible dose-response pattern than did the primary end-
point analysis. Post-hoc FDA response for abdominal pain
was signiﬁcantly greater than placebo for the 100-mg
eluxadoline group, and stool consistency response dis-
played a more dose-proportional response with superiority
over placebo observed for the 200-mg eluxadoline group
(P < .10 for the 100-mg eluxadoline group). The higher
dropout rate in the 200-mg eluxadoline group and lack of
data imputation for those dropouts may contribute to the
failure of that dose to achieve superiority over placebo for
the pain responses during the 12-week study interval used
in the post-hoc analyses.
The most common adverse events reported were those
of the gastrointestinal system. Gastrointestinal adverse
events, including nausea, vomiting, and abdominal pain,
were more frequently reported in the 200-mg eluxadolinegroup, suggestive of a continuum of eluxadoline’s local
pharmacological effects on the gut. The higher incidence
of abdominal pain reported in the 200-mg eluxadoline
group might also contribute to the lack of efﬁcacy seen
for pain response in this dose group. Although the inci-
dence rate of constipation was higher in the 100-mg
eluxadoline group, the events were generally mild in in-
tensity and were tolerated by the patients without
requiring discontinuation of study drug. The most
notable safety ﬁnding among patients receiving eluxado-
line was infrequent reports of pancreatitis, including 2
cases that occurred after only 1 or 2 doses of study drug.
Although 2 of the 4 total pancreatitis cases were
confounded by mitigating factors (one patient with high
blood alcohol level at the onset of the event and another
patient who was off study drug for 2 weeks at the onset of
the event), a possible relationship to eluxadoline treat-
ment could not be ruled out because of the known as-
sociation between opioids and acute pancreatitis and the
lack of any such events among placebo-treated patients in
this study.17 After the last case, the protocol was amended
to exclude patients who might have been predisposed to
pancreatitis, that is, those with histories of pancreatitis,
biliary duct disease, sphincter of Oddi dysfunction, alcohol
abuse, binge drinking, elevated serum lipase, or cholecys-
tectomy. The rationale for excluding patients with
sphincter of Oddi dysfunction was based on the knowledge
that patients experiencing sphincter of Oddi dysfunction
are sensitive to opioids and can experience severe abdominal
pain and pancreatitis, even after a single dose of opioid-
containing medications.18 Importantly, after implementa-
tion of the amendment, no additional events of pancreatitis
were reported among the 210 patients enrolled. Future
studies will need to prospectively evaluate the potential as-
sociation between pancreatitis and eluxadoline treatment
and also evaluate whether the exclusionary precautions
implemented in the current study might minimize any
potential risk.
Overall, the results from the current study conﬁrm the
effectiveness of eluxadoline to manage IBS-D based on a
composite response of abdominal pain and stool consis-
tency without signiﬁcant risk of constipation. These re-
sults also suggest that additional clinical development of
eluxadoline is warranted to validate the clinical mean-
ingfulness of the composite end point and to determine
what baseline patient characteristics are predictive of
clinical response with eluxadoline.Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at http://
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Supplementary Figure 1. Patient disposition. The “other” category includes IVRS-conﬁrmed constipation, lack of efﬁcacy, physician decision, and
sponsor decision; AE, adverse event, DC, discontinued, ITT, intent-to-treat, IVRS, interactive voice response system, LTFU, lost to follow-up.
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